These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 1381762)
1. Concentration/effect relationship and enantioselective analysis of verapamil in hypertensive patients. Harder S; Thürmann P; Siewert M; Blume H; Rietbrock N; vander Kleijn J; Gierend M J Cardiovasc Pharmacol; 1992 May; 19(5):665-9. PubMed ID: 1381762 [TBL] [Abstract][Full Text] [Related]
2. Serum concentration and antihypertensive effect of slow-release verapamil. Schütz E; Ha HR; Bühler FR; Follath F J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566 [TBL] [Abstract][Full Text] [Related]
3. Concentration/effect relationship of bunazosin, a selective alpha 1-adrenoceptor antagonist in hypertensive patients after single and multiple oral doses. Harder S; Thürmann P Int J Clin Pharmacol Ther; 1994 Jan; 32(1):38-43. PubMed ID: 7911057 [TBL] [Abstract][Full Text] [Related]
4. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram]. Canonico V; Bonaduce D; De Caprio L; Nicolino A; Forgione L; Petretta M; Rengo F G Ital Cardiol; 1990 Oct; 20(10):924-32. PubMed ID: 2090531 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions. Aarons L; Baxter C; Gupta S Biopharm Drug Dispos; 2004 Jul; 25(5):219-25. PubMed ID: 15248191 [TBL] [Abstract][Full Text] [Related]
6. Twice-daily administration of oral verapamil in the treatment of essential hypertension. Frishman W; Charlap S; Kimmel B; Saltzberg S; Stroh J; Weinberg P; Monuszko E; Wiezner J; Dorsa F; Pollack S Arch Intern Med; 1986 Mar; 146(3):561-5. PubMed ID: 3954530 [TBL] [Abstract][Full Text] [Related]
7. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410 [TBL] [Abstract][Full Text] [Related]
8. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Kang D; Verotta D; Krecic-Shepard ME; Modi NB; Gupta SK; Schwartz JB Clin Pharmacol Ther; 2003 Jan; 73(1):31-40. PubMed ID: 12545141 [TBL] [Abstract][Full Text] [Related]
9. Concentration/effect analysis of verapamil: evaluation of different approaches. Harder S; Rietbrock S; Thürmann P Int J Clin Pharmacol Ther Toxicol; 1993 Oct; 31(10):469-75. PubMed ID: 8262684 [TBL] [Abstract][Full Text] [Related]
10. [The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil]. Widimský J; Dzúrik R Vnitr Lek; 1998 Jun; 44(6):326-31. PubMed ID: 9820054 [TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of S-verapamil after single doses of two different galenic formulations of racemic verapamil. Harder S; Siewert M; Thürmann P; Blume H; Rietbrock N; Siewert B Arzneimittelforschung; 1993 May; 43(5):520-2. PubMed ID: 8328995 [TBL] [Abstract][Full Text] [Related]
14. Relationships between verapamil plasma concentrations and its antihypertensive action. Gonzalez-Gomez A; Cires Pujols M; Gamio Capestany F; Rodriguez de la Vega A; Garcia-Barreto D Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):453-60. PubMed ID: 3198301 [TBL] [Abstract][Full Text] [Related]
15. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. Karim A; Piergies A Clin Pharmacol Ther; 1995 Aug; 58(2):174-84. PubMed ID: 7648767 [TBL] [Abstract][Full Text] [Related]